Ph.D., immunogenetics. MHC epitope definition, dark ages. Quite retail. Not investment advice.
Joined May 2009
- Tweets 6,628
- Following 156
- Followers 757
- Likes 9,858
44 Photos and videos
$BDTX.... had not seen this... "Silevertinib in Treatment-Naive Patients With Non-Classical EGFR Mutations: Dr. Rotow Shares Insights..." lungcancerstoday.com/post/si…
1
2
225
Jun 2
$BDTX S241656 (AKA BDTX-4933)....
Jun 2
🇨🇳 China IND Tracker (May 25–30)
10 innovative drugs received their first IND clearances in China last week.
Notable INDs
1⃣ GenSci144 Tablets – GeneSci (金赛药业)
MOA: SLC6A19 inhibitor
Indication: Phenylketonuria (PKU)
2⃣ HL‑400 Sustained‑Release Tablets – Highlight Pharmaceutical (高光制药)
MOA: Brain‑penetrant NLRP3 inhibitor
Indication: Parkinson’s disease
3⃣ LY4005130 Injection – $LLY
MOA: Not disclosed (biologic)
Indications:
• Adult non‑segmental vitiligo
• Adult severe alopecia areata
4⃣ S241656 Tablets – Servier
MOA: RAF inhibitor
Indication: Malignancies with confirmed KRAS, BRAF, or other RAS/MAPK pathway mutations
5⃣ SNH‑118110 Soft Capsules – ScinnoHub Pharmaceutical (赛诺哈勃)
MOA: Third‑generation RET inhibitor
Indication: Advanced solid tumors with RET alterations
6⃣ GA002 Injection – Genans Biotech (健达九州)
MOA: Gene therapy using rAAV to deliver an engineered inhibitory GPCR
Indication: Refractory epilepsy
GA002 selectively suppresses hyperexcitable neurons via a paired small‑molecule ligand, reducing epileptiform discharges.
7⃣ MST‑168 Monoclonal Antibody for Injection – MabSoft Therapeutics (慕宝盛科生物)
MOA: Bioconjugate antibody (target undisclosed)
Indication: HER2‑driven advanced solid tumors
3
3
1,700
Jun 15
2/ "Update and Latest Advances with Phase 0 Clinical Trials in Neuro-Oncology", session title "Cross-Cutting Novel Delivery Platforms - Getting There". virtual.oxfordabstracts.com/…
1
155
Jun 16
3/ Trial is still recruiting. Estimated final recruitment is 82, with primary completion estimated as 12/26. We've only had info from the first 27 patients, so SNO could be info-packed, with luck, for sil.
1
128
Spontonic retweeted
Jun 15
are u saying none of the laureates took off their shirt and yelled about Mamie Eisenhower’s package ?
18
27
1,078
28,747
Jun 13
Indirect, but more evidence that anti-IL-27 is at best a two-edge sword. Blocking a pathway that induces IL-10 is a gamble. Nothing shockingly new for Dr. LaVallee, she addresses this sort of concern/context upfront.
Jun 13
3.5% of patients with inflammatory bowel disease (Crohn’s and ulcerative colitis) have autoantibodies against the anti-inflammatory cytokine, IL-10.
This is a stunning discovery that shows just how heterogeneous IBD is — and highlights the need for personalized therapy.
4
401
Jun 4
5/ Velleca has path narrowed again, and clearly describes a "fast trial" route to adjuvant setting. But if he has ANY offers on the table (buyout) from deep pocket partners? He should take one. Now. Period. Don't miss his presentation.
121
